What is Oral Tolerance?

doi:10.21127/yaoyimr20180012

Medicine Research ›› 2018, Vol. 2 ›› Issue (3): 180012-.DOI: 10.21127/yaoyimr20180012

• Minireview • Previous Articles Next Articles

What is Oral Tolerance?

Jingjing Chen^a, Wenhui Wu^{a, b, *}

^a College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China;
^b Shanghai Engineering Research Center of Aquatic-Product Processing & Preservation, Shanghai 201306, China

Received:2018-09-03 Revised:2018-09-09 Online:2018-11-24 Published:2018-11-24
Supported by:
The work was supported by the National Natural Science Foundation of China (No. 81502955), the Doctoral Scientific Research Foundation of Shanghai Ocean University (No. A2030214300077), the Young Teachers’ Training Program of Shanghai (No. A12056160002), the Plan of Innovation Action in Shanghai (No. 14431906000), and the Project Funded by Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening.

Abstract

Abstract: Oral tolerance can be defined as the specific inhibition of the humoral and cellular immune response of an antigen by administration of the same antigen via the oral route. Because of its lack of toxicity, ease of administration and antigen specificity, oral tolerance is a very attractive approach for the treatment of autoimmune and inflammatory diseases. A variety of mechanisms have been proposed to explain the immune hyporesponsiveness to feeding antigens. It has been reported that low doses of orally administered antigens are beneficial for the production of regulatory cells, while high doses favor anergy or clonal deletion. In this paper, we discuss the mechanisms of oral tolerance induction.

Key words: oral tolerance, regulatory T cells, anergy, clonal deletion

Jingjing Chen, Wenhui Wu. What is Oral Tolerance?[J]. Medicine Research, 2018, 2(3): 180012-.

References

[1]Weiner, H. L. Ann. N. Y. Sci. 2010, 1029, 211.
[2]Rezende, R. M.; Weiner. H. L. Semin. Immunol. 2017,30, 3.
[3]Brandtzaeg, P. Nutr. Rev.1998, 56, 5.
[4]Macfarlane, G. T.; Macfarlane S. Scand. J. Gastroenterol. 1997, 222, 3.
[5]Du, P. M.; Samsom J. N. Allergy 2011, 66, 478.
[6]Faria, A. M.; Weiner, H. L. Immunol. Rev. 2005, 206, 232.
[7]Lefrançois, L.; Puddington, L. Ann. Rev. Immunol. 2006, 24, 681.
[8]Brandtzaeg, P.; Kiyono, H.; Pabst, R.; Russell, M. W. Mucosal. Immunol. 2008, 1, 31.
[9]Spahn ,T. W.; Fontana, A.; Faria, A. M.; ,A.J.; Eugster, H. P.; Zhang, X.; Koni, P. A.; Ruddle, N. H.; Flavell, R. A.; Rennert, P. D.; Weiner, H. L. Eur. J. Immunol. 2015, 31, 1278.
[10]Spahn, T. W.; Weiner, H. L.; Rennert, P. D.; Lugering, N.; Fontana, A.; Domschke, W.; Kucharzik, T. Eur. J. Immunol. 2015, 32, 1109.
[11]Fujihashi, K.; Dohi, T.; Rennert, P. D.; Yamamoto, M.; Koga, T.; Kiyono, H.; McGhee, J. R. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 3310.
[12]Worbs, T.; Bode, U.; Yan, S.; Hoffmann, M. W.; Hintzen, G.; Bernhardt, G. J. Exp. Med. 2006, 203, 519.
[13]Resciqno, M. Adv. Immunol. 2010, 107, 109.
[14]Wang, X.; Shrman, A.; Liao, G.; Leong, K. W.; Daniell, H.; Terhorst, C.; Herzog, R. W. Adv. Drug Deliv. Rev. 2013, 65, 759.
[15]Friedman, A.; Weiner, H. L. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 6688.
[16]Shevach, E. M. Immunity 2009, 30,636.
[17]Chen, Y.; Inobe, J.; Marks, R.; Gonnella, P.; Kuchroo, V.; Weiner, H. L. Nature 1995, 376, 177.
[18]Marth, T.; Zeitz, M.; Ludviksson, B.; Strober, W.; Kelsall, B. Ann. N. Y. Acad. Sci. 2010, 859, 290.
[19]Chen, Y.; Kuchroo, V. K.; Inobe, J.; Hafler, D. A.; Weiner, H. L. Science 1994, 265, 1237.
[20]Sakaguchi, S.; Sakaguchi, N.; Asano, M.; Itoh, M.; Toda, M. J. Immunol. 2011, 186, 3808.
[21]Ramsdell, F. Immunity 2003, 19, 165.
[22]Nakamura, K.; Kitani, A.; Fuss, I.; Pedersen, A.; Harada, N.; Nawata, H. J. Immunol. 2004, 172, 834.
[23]den Haan, J. M.; Bevan, M. J. Curr. Opin. Immunol. 2001, 13, 437.
[24]Belkaid, Y. Nat. Rev. Immunol. 2007, 7, 875.
[25]Basten, A.; Fazekas, d. S. G. B. Immunology 2010,123, 33.
[26]Levy, L.; Ilan, Y. Recent Pat. AntiInfect. Drug Discov. 2007, 2, 217.
[27]Belkaid, Y.; Rouse, B. T. Nat. Immunol. 2005, 6, 353.
[28]Allez, M.; Mayer, L. Gastroenterology 2003, 124, 481.
[29]Kazuyuki, T.; Takayuki, O.; Harumi, S.; Manabu, O.; Tetsuo, N.; Takeji, N.; Masayuki, A.; Shigeo, K. Eur. J. Immunol. 2002, 32, 627.
[30]Chen, M. L.; Yan, B. S.; Bando, Y., Kuchroo, V. K., Weiner, H. L. J. Immunol. 2008,180, 7327.
[31]Allez, M.; Mayer, L. Gastroenterology 2002, 123, 1516.
[32]Arnaboldi, P. M.; Roth-Walter, F.; Mayer, L. Mucosal. Immunol. 2009, 2, 427.
[33]Brimnes, J.; Allez, M.; Dotan, I.; Shao, L.; Nakazawa, A.; Mayer, L. Ann. N. Y. Acad. Sci. 2010, 1029, 22.
[34]van den Berg, H.; Greuter, M.; Kraal, G.; den Haan, J. M. Immunobiology 2010, 215, 163.
[35]Ochi, H.; Abraham, M.; Ishikawa, H.; Frenkel, D.; Yang, K.; Basso, A. S. Nat. Med. 2006, 12, 627.
[36]Barnett, M. L.; Kremer, J. M.; St Clair, E. W.; Clegg, D. O.; Furst, D.; Weisman, M. Arthritis. Rheum. 2010, 41, 290.
[37]Bagchi, D.; Misner, B.; Bagchi, M. Int. J. Clin. Pharmacol. Res. 2002, 22, 101.
[38]Gong, Z.; Jin, Y.; Zhang, Y. Vaccine 2007, 25, 1444.

What is Oral Tolerance?

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	Carita Sallomy, Maija Lahtela-Kakkonen, and Juri M. Timonen. Recent Advances on Molecular Modeling Studies of Transient Receptor Potential Ankyrin 1 [J]. Medicine Research, 2021, 5(1): 200021-200021.
[2]	Titi Liu, Chengting Zi, Xuanjun Wang, Jun Sheng, and Huanhuan Xu. Recent Advances on Interaction Targets for Anticancer Activity of Caffeine [J]. Medicine Research, 2021, 5(1): 200020-200020.
[3]	Zhao Wang, Filipe Olim, Jingjing Sun, Ana Rute Neves, Fátima Mendes, Helena Tomás, and Ruilong Sheng. Prodrug Systems (II): A Perspective of Polymer-Based Doxorubicin Prodrug Systems towards Chemotherapy [J]. Medicine Research, 2021, 5(1): 200023-200023.
[4]	Xiu-Li Sun, Yin-Rong Xie, Ning Zhang, Cheng-Ting Zi, Xuan-Jun Wang, and Jun Sheng. Recent Advances on Small-Molecule Tubulin Inhibitors [J]. Medicine Research, 2021, 5(1): 200024-200024.
[5]	Zhonglie Yang, Li Lin, Xiaoyan Peng, Xinyi Yu, Xiaobin Zhang, Hezhong Jiang, and Jiahong Li. Adverse Reactions and Resistance of Anticancer Drug Cisplatin [J]. Medicine Research, 2021, 5(1): 200022-200022.
[6]	Jinyu Yi, Yingying Huang, and Chaoyan Zhang. Bletilla striata Polysaccharides: Structures and Functional Activities [J]. Medicine Research, 2020, 4(4): 200009-0.
[7]	Alessandra Campbell Pinheiro, Sarah Sant’Anna Maranhão, Guilherme Graziany Camelo Carvalho, Augusto César Aragão Oliveira, Cláudia Pessoa, Thaís Cristina Mendonça Nogueira, Cristiane França da Costa, Marcus Vinícius Nora de Souza. Synthesis and Cytotoxic Activity of Arenecarbaldehyde 2-Pyridinylhydrazone Derivatives [J]. Medicine Research, 2020, 4(4): 200016-200016.
[8]	Xiao-Jing Shen, Ting-Ting Zheng, Hong Wang, Jiao Cai, Cheng-Ting Zi, and Jiang-Ping Fan. Progress in Antitumor Activity of Diterpenoid Alkaloids [J]. Medicine Research, 2020, 4(4): 200015-200015.
[9]	Xiaodi Li, Rui Liu, Ping Wang, and Jun Zhu. An Effective Inhibitory of Triptolide on Ovarian Cancer [J]. Medicine Research, 2020, 4(4): 200017-200017.
[10]	Kuo Xu, Qian Liu, Lin Ni, Yong-Mei Du and Zhong-Feng Zhang. An Update on Chemical Constituents from Nicotiana tabacum L. and Their Bioactivities from 2017 to 2020 [J]. Medicine Research, 2020, 4(4): 200019-200019.
[11]	Hao Wang, Ji-Lei Liang, Qing-Ming He, Guo-Hai Zhou, Cun-Fu Li, Ping-He Wei, and Hao-Yan Dong. Flavonoids, Phenylethanoids and Phenylpropanoids from Rhodiola rosea L. and Their Lipid-Lowering Activities on Receptor 5-HT_2A [J]. Medicine Research, 2020, 4(4): 200018-200018.
[12]	. Contents: Med. Res. 4/2020 [J]. Medicine Research, 2020, 4(4): 0-0.
[13]	Xiaojing Shena , Weiwei Jiang. Polysaccharides from Bletilla striata: Extraction, Optimization and Their Antioxidant Activities in vitro [J]. Medicine Research, 2020, 4(3): 200010-.
[14]	Bo-Ya Shi, Ze-Hao Wang, Xuan-Jun Wang Jun Sheng, and Cheng-Ting Zi. Recent Advances on Small-Molecule Epidermal Growth Factor Receptor Inhibitors [J]. Medicine Research, 2020, 4(3): 200011-.
[15]	Yingying Huang, Jinyu Yi, Chaoyan Zhang. Progress in Percutaneous Penetration Enhancers from Traditional Chinese Medicines [J]. Medicine Research, 2020, 4(3): 200008-.